Fungal Infections are a major cause of human disease. An estimated 11.5 million (M) people suffer from life-threatening infections globally, resulting in more than 1.5M deaths annually and infections of the skin, nail and hair are estimated to affect ~1 billion (B) people globally (Review). The four classes of antifungal drugs to treat life-threatening infections have limitations, including toxicity, drug-drug interactions, inconvenient dosing, and increasing incidence of resistance. There is an urgent need to discover and develop the next generation of antifungal drugs. The growing threat of drug-resistant fungi prompted the US Centers of Disease Control to add drug resistant Candida spp., Aspergillus fumigatus and C. auris to its “Serious”, “Watch List” and “Urgent Threats” in their 2019 ANTIBIOTIC RESISTANCE THREATS REPORT (Report).
Kathera Bioscience Inc. has assembled a world class team of industry experts, advisors, consultants, and academic leaders, and innovative proprietary technology to develop the next generation of antifungal drugs. The team has expertise in fungal biology and decades of experience in the pharmaceutical and biotech industries, as well as academia. The team’s expertise spans all aspects of pharma and biotech Research & Development including target identification and validation, lead identification, lead optimization, preclinical development, and project management.
The KatheraBio antifungal technology targets novel fungal enzymes for which there are no FDA-approved drugs on the market. We believe that a drug inhibiting our molecular target can be used as monotherapy or in combination with existing antifungal drugs to treat infections caused by drug-resistant fungi.